Log in

Company updateCNBC-TV18

Biocon gets European Commission's market authorisation for biosimilar for breast cancer treatment

Positive+20

GreyOak summary

Biocon Ltd. received European Commission market authorization for Pebrilzo, its biosimilar pertuzumab, to treat HER2-positive breast cancer. This marks the company's fifth oncology biosimilar approval globally. The news follows a recent quarterly report showing a 57.4% decline in net profit to ₹56.7 crore.

What it affects

Source

Read the original at CNBC-TV18

More Biocon news

All Biocon news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy